Steroids and Osteoarthritis

Perkins, Celine; Whiting, Bethan; Lee, Paul Yf

doi:10.4172/2167-7921.1000e115

Cited by 4 publications

(3 citation statements)

References 27 publications

(27 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Corticosteroids, including DEX, have been considered potent anti-inflammatory agents for the treatment of RMDs and have been used for more than 50 years to treat OA and RA pain . A number of preclinical and clinical studies have demonstrated that DEX inhibits inflammation and joint tissue damage. ,,, For instance, a clinical study assessed patients’ positive functional mobility and pain relief when DEX was administered by applying phonophoresis with ultrasound on knee OA .…”

Section: Dexamethasone For the Treatment Of Joint Disordersmentioning

confidence: 99%

Dexamethasone: Insights into Pharmacological Aspects, Therapeutic Mechanisms, and Delivery Systems

Madamsetty

Mohammadinejad

Uzielienè

et al. 2022

ACS Biomater. Sci. Eng.

View full text Add to dashboard Cite

Dexamethasone (DEX) has been widely used to treat a variety of diseases, including autoimmune diseases, allergies, ocular disorders, cancer, and, more recently, COVID-19. However, DEX usage is often restricted in the clinic due to its poor water solubility. When administered through a systemic route, it can elicit severe side effects, such as hypertension, peptic ulcers, hyperglycemia, and hydro-electrolytic disorders. There is currently much interest in developing efficient DEX-loaded nanoformulations that ameliorate adverse disease effects inhibiting advancements in scientific research. Various nanoparticles have been developed to selectively deliver drugs without destroying healthy cells or organs in recent years. In the present review, we have summarized some of the most attractive applications of DEX-loaded delivery systems, including liposomes, polymers, hydrogels, nanofibers, silica, calcium phosphate, and hydroxyapatite. This review provides our readers with a broad spectrum of nanomedicine approaches to deliver DEX safely.

show abstract

Section: Dexamethasone For the Treatment Of Joint Disordersmentioning

confidence: 99%

Dexamethasone: Insights into Pharmacological Aspects, Therapeutic Mechanisms, and Delivery Systems

Madamsetty

Mohammadinejad

Uzielienè

et al. 2022

ACS Biomater. Sci. Eng.

View full text Add to dashboard Cite

show abstract

“… 14 , 15 Another common method for short-term relief of OA is an intra-articular injection of corticosteroids. These local injections have fewer systemic side effects and have demonstrated the ability to decrease inflammation and pain levels 16 ; however, the evidence regarding long-term efficacy of these treatments is limited, 17 and in vitro and in vivo evidence has shown that cortisone injections are chondrotoxic with dose-dependent deleterious effects on cartilage. 18 Similarly, viscosupplementation, involving intra-articular hyaluronic acid (HA) injections, is used in an attempt to improve joint lubrication.…”

Section: Current Treatment Strategies For Oamentioning

confidence: 99%

Perinatal Tissue–Derived Allografts and Stromal Cells for the Treatment of Knee Osteoarthritis: A Review of Preclinical and Clinical Evidence

et al. 2022

View full text Add to dashboard Cite

Objective The use of perinatal-derived tissues and mesenchymal stromal cells (MSCs) as alternative treatment options to corticosteroid and hyaluronic acid injections has been gaining popularity. However, their ability to attenuate osteoarthritic (OA) symptoms while also slowing the progression of the disease remains controversial. Thus, the objective of this article is to summarize the results from both preclinical and clinical studies evaluating the efficacy of perinatal-derived tissue allografts and MSCs for the treatment of OA. Design A comprehensive literature search was conducted on databases including Pubmed, ScienceDirect, and Google Scholar beginning in March 2020 for both preclinical and clinical studies evaluating perinatal-derived tissues and MSCs in OA. Eighteen studies met the inclusion criteria and were used for this review. Results Both animal models and early human clinical trials demonstrated that perinatal tissues could reduce joint inflammation and pain as well as improve range of motion and function in OA. Perinatal tissue–derived MSCs in animal studies have shown the potential to support chondrocyte proliferation while also decreasing inflammatory gene and protein expression. Limited clinical results suggest perinatal tissue–derived MSC sources may also be a viable alternative or adjunct to hyaluronic acid in reducing pain and symptoms in an arthritic joint. Conclusions Perinatal tissue–derived allografts and MSCs have promise as potential therapeutics for mitigating OA progression. However, further research is warranted to fully define the therapeutic mechanism(s) of action and safety of these biological therapies.

show abstract

“…Moreover, corticosteroids are more potent anti-inflammatory medications than non-steroidal anti-inflammatory drugs, especially in rheumatoid arthritis (19). They can be used widely as intra-articular injections for osteoarthritis and rheumatoid arthritis treatment, however, when considering long term usage, the benefits of the corticosteroid injections are poor and display adverse effects when were given at long durations such as hot flashes, subcutaneous atrophy, risk of infection, skin depigmentation, muscle weakness, suppression of adrenal glands and growth retardation (20)(21)(22). Consequently, the use of corticosteroids (40 mg/dose) is limited from three to four intra-articular injections annually with at least three-months gap between the injections (23,24).…”

Section: Introductionmentioning

confidence: 99%

Polymer colloids as drug delivery systems for the treatment of arthritis

Saeedi

Alotaibi

Prokopovich

2020

Advances in Colloid and Interface Science

View full text Add to dashboard Cite

The most common types of arthritis are osteoarthritis (OA) and rheumatoid arthritis (RA) which are themain causes of disability and pain among older people. Current treatment of arthritis mainly consists of oral and intra-articular medications. Despite the efficacy of the intraarticular injections over the oral treatment, it is still limited by the rapid clearance of the injected drug. Therefore, a rational design of drug delivery systems (DDSs) able to delivery drugs in controlled manner and for required period of time to the arthritis joint is a key in developing safe and effective formulations for OA and RA. In this paper various colloidal systems like nanoparticles, liposomes, cationic carriers, hydrogels, and emulsion-based carriers were presented and discussed in light of their use and efficacy as delivery systems to transport therapeutics for arthritis treatment. Factors influencing the delivery efficacy such as size, charge, structure, drug uptake, retention and its release profile alongside with cytocompatibility and safety were addressed. Moreover, the advantages and disadvantages of the different colloidal systems were emphasised.

show abstract

Steroids and Osteoarthritis

Cited by 4 publications

References 27 publications

Dexamethasone: Insights into Pharmacological Aspects, Therapeutic Mechanisms, and Delivery Systems

Dexamethasone: Insights into Pharmacological Aspects, Therapeutic Mechanisms, and Delivery Systems

Perinatal Tissue–Derived Allografts and Stromal Cells for the Treatment of Knee Osteoarthritis: A Review of Preclinical and Clinical Evidence

Polymer colloids as drug delivery systems for the treatment of arthritis

Contact Info

Product

Resources

About